title: [Standardized controlled antitubercular therapy and results in 755 patients].
abstract: 755 patients were treated because of tuberculosis from 1984-1989. The treatment was standardized according to the recommendations. INH and RMP were used in over 95% as in the hospital as in the ambulatory phase. During the period of 6 yrs. the use of SM was markedly reduced (21.8%) while the use of PZA increased from 14.6% to 55.0%. At least four drugs were used in 22.5%. In 36.2% mycobacteria were found only before starting treatment. After four weeks treatment further 45.1% were negative. Adverse reactions were registered in 9.3%. Concomitant diseases rendering the treatment were observed in 24.7%. Ten patients died because of tuberculosis. Until now only 3 patients had relapses. Controlled treatment is valuable and therefore recommended.
authors.affiliation: Klinik für Lungenkrankheiten und Tuberkulose, Zentralklinik für Herz- und Lungenkrankheiten Bad Berka.
authors.forename: B
authors.initials: B
authors.lastname: Wiesner
authors.forename: G
authors.initials: G
authors.lastname: Cramer
authors.forename: U
authors.initials: U
authors.lastname: Hamel
authors.forename: G
authors.initials: G
authors.lastname: Roth
mesh_terms: D000328:Adult; D000368:Aged; D000995:Antitubercular Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011718:Pyrazinamide / Q000627:therapeutic use; D012008:Recurrence; D012293:Rifampin / Q000627:therapeutic use; D013183:Sputum / Q000382:microbiology; D013307:Streptomycin / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000995:Antitubercular Agents; D011718:Pyrazinamide; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin
vernacular_title: Standardisierte kontrollierte antituberkulotische Therapie und Ergebnisse bei 755 Patienten.